SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-016013
Filing Date
2023-05-05
Accepted
2023-05-05 09:23:40
Documents
68
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ovid-20230331.htm   iXBRL 10-Q 1214822
2 EX-31.1 ovid2023q1exhibit311.htm EX-31.1 10660
3 EX-31.2 ovid2023q1exhibit312.htm EX-31.2 10697
4 EX-32.1 ovid2023q1exhibit321.htm EX-32.1 5782
10 ovid-20230331_g1.jpg GRAPHIC 111156
  Complete submission text file 0001628280-23-016013.txt   5823641

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ovid-20230331.xsd EX-101.SCH 44321
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ovid-20230331_cal.xml EX-101.CAL 55862
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ovid-20230331_def.xml EX-101.DEF 155256
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ovid-20230331_lab.xml EX-101.LAB 519315
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ovid-20230331_pre.xml EX-101.PRE 326064
62 EXTRACTED XBRL INSTANCE DOCUMENT ovid-20230331_htm.xml XML 714361
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38085 | Film No.: 23891581
SIC: 2834 Pharmaceutical Preparations